BEAM - 3 Cathie Wood Stocks That Could Deliver Monster Returns
2022 has been brutal for early-stage biotech companies. Cathie Wood's Ark Genomic Revolution ETF is down 60% over the past year. Wood's long-term performance is outstanding, however, even after that huge drop. Some of her stocks have gotten a lot cheaper in the short term. But the potential upside remains huge.
Our roundtable group dug into her holdings and found three stocks that we particularly like. Here's why we're bullish on 10x Genomics (NASDAQ: TXG) , Beam Therapeutics (NASDAQ: BEAM) and Recursion Pharmaceuticals (NASDAQ: RXRX) .
Image source: Getty Images.
For further details see:
3 Cathie Wood Stocks That Could Deliver Monster Returns